GB9801690D0
(en)
*
|
1998-01-27 |
1998-03-25 |
Pfizer Ltd |
Therapeutic agents
|
IL137511A0
(en)
*
|
1998-01-28 |
2001-07-24 |
Shionogi & Co |
Novel tricyclic compound
|
YU57101A
(sh)
*
|
1999-02-08 |
2005-06-10 |
G.D. Saerle & Co. |
Sulfamat hidroksamična kiselina inhibitor metaloproteaze
|
US6800646B1
(en)
|
1999-02-08 |
2004-10-05 |
Pharmacia Corporation |
Sulfamato hydroxamic acid metalloprotease inhibitor
|
GB9912961D0
(en)
*
|
1999-06-03 |
1999-08-04 |
Pfizer Ltd |
Metalloprotease inhibitors
|
US6511993B1
(en)
*
|
1999-06-03 |
2003-01-28 |
Kevin Neil Dack |
Metalloprotease inhibitors
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
EP1261595A1
(de)
*
|
2000-02-21 |
2002-12-04 |
AstraZeneca AB |
Arylpiperazin- und arypiperidin-derivate und ihre verwendung als metalloproteinase hemmende wirkstoffe
|
JO2409B1
(en)
|
2000-11-21 |
2007-06-17 |
شركة جانسين فارماسوتيكا ان. في |
Second-phenyl carboxy amides are useful as lipid-lowering agents
|
EP1399483B1
(de)
|
2001-01-05 |
2010-04-14 |
Pfizer Inc. |
Antikörper gegen den rezeptor für den insulinähnlichen wachstumsfaktor i
|
GB0108102D0
(en)
*
|
2001-03-30 |
2001-05-23 |
Pfizer Ltd |
Compounds
|
US6821972B2
(en)
|
2001-03-30 |
2004-11-23 |
Pfizer Inc. |
3-heterocyclylpropanohydroxamic acid PCP inhibitors
|
AU2002345792A1
(en)
|
2001-06-21 |
2003-01-08 |
Pfizer Inc. |
Thienopyridine and thienopyrimidine anticancer agents
|
GB0119474D0
(en)
|
2001-08-09 |
2001-10-03 |
Astrazeneca Ab |
Compounds
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
CA2470214A1
(en)
*
|
2001-12-13 |
2003-06-26 |
Abbott Laboratories |
3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer
|
KR100984573B1
(ko)
|
2002-03-13 |
2010-09-30 |
어레이 바이오파마 인크. |
Mek 억제제로서의 n3 알킬화 벤즈이미다졸 유도체
|
US20050209278A1
(en)
*
|
2002-04-25 |
2005-09-22 |
Mcdonald Joseph J |
Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
|
MXPA04010555A
(es)
*
|
2002-04-25 |
2005-02-17 |
Pharmacia Corp |
Acidos piperidinil- y piperazinil-sulfonilmetil hidroxamicos y su uso como inhibidores de proteasa.
|
UA77303C2
(en)
|
2002-06-14 |
2006-11-15 |
Pfizer |
Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
|
BR0312036A
(pt)
*
|
2002-06-25 |
2005-04-05 |
Pharmacia Corp |
ácido arilsulfonilhidroxâmico e derivados de amida bem como composição farmacêutica contendo os mesmos e uso dos mesmos
|
WO2004048368A2
(en)
*
|
2002-11-25 |
2004-06-10 |
Pharmacia Corporation |
Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors
|
PL377713A1
(pl)
|
2002-12-19 |
2006-02-06 |
Pfizer Inc. |
Związki 2-(1H-indazol-6-iloamino)benzamidowe jako inhibitory kinaz białkowych użyteczne w leczeniu chorób oczu
|
DE60323155D1
(de)
*
|
2002-12-19 |
2008-10-02 |
Scripps Research Inst |
Von transthyretin und zur hemmung von transthyretin-fehlfaltung
|
ATE457716T1
(de)
|
2002-12-30 |
2010-03-15 |
Angiotech Int Ag |
Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
|
KR101106905B1
(ko)
|
2003-02-26 |
2012-01-25 |
수젠, 인크. |
단백질 키나아제 억제제로서의 아미노헤테로아릴 화합물
|
US7144907B2
(en)
|
2003-09-03 |
2006-12-05 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
AU2004293017B2
(en)
|
2003-11-19 |
2010-08-19 |
Array Biopharma Inc. |
Bicyclic inhibitors of MEK and methods of use thereof
|
US20080319175A1
(en)
|
2004-05-20 |
2008-12-25 |
The Scripps Research Institute |
Transthyretin Stabilization
|
EA013678B1
(ru)
|
2004-08-26 |
2010-06-30 |
Пфайзер Инк. |
Энантиомерно чистые аминогетероарильные соединения в качестве ингибиторов протеинкиназы
|
MY146381A
(en)
|
2004-12-22 |
2012-08-15 |
Amgen Inc |
Compositions and methods relating relating to anti-igf-1 receptor antibodies
|
US7429667B2
(en)
|
2005-01-20 |
2008-09-30 |
Ardea Biosciences, Inc. |
Phenylamino isothiazole carboxamidines as MEK inhibitors
|
ES2378760T3
(es)
|
2005-05-18 |
2012-04-17 |
Array Biopharma, Inc. |
Inhibidores heterocíclicos de MEK y métodos de uso de los mismos
|
US8101799B2
(en)
|
2005-07-21 |
2012-01-24 |
Ardea Biosciences |
Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
|
CN101365446B
(zh)
|
2005-07-29 |
2013-05-22 |
雷斯弗洛吉克斯公司 |
预防和治疗复杂疾病的药物组合物及其经由可植入医药装置的递送
|
DK1926996T3
(da)
|
2005-09-20 |
2012-01-23 |
Osi Pharmaceuticals Llc |
Biologiske markører, som er prædiktive for anti-cancer-reaktion på insulinlignende vækstfaktor-1-receptorkinasehæmmere
|
TWI405756B
(zh)
|
2005-12-21 |
2013-08-21 |
Array Biopharma Inc |
新穎硫酸氫鹽
|
US7842836B2
(en)
|
2006-04-11 |
2010-11-30 |
Ardea Biosciences |
N-aryl-N'alkyl sulfamides as MEK inhibitors
|
JP5269762B2
(ja)
|
2006-04-18 |
2013-08-21 |
アーディア・バイオサイエンシーズ・インコーポレイテッド |
Mek阻害剤としてのピリドンスルホンアミドおよびピリドンスルファミド
|
EP2074223A4
(de)
*
|
2006-09-15 |
2010-03-10 |
Foldrx Pharmaceuticals Inc |
Testverfahren zum nachweis von proteinen im nativen zustand und zur identifizierung von die stabilität von proteinen im nativen zustand modulierenden verbindungen
|
JP2010513263A
(ja)
|
2006-12-15 |
2010-04-30 |
ファイザー・プロダクツ・インク |
ベンズイミダゾール誘導体
|
EP2121620B1
(de)
|
2007-01-19 |
2015-06-17 |
Ardea Biosciences, Inc. |
Mek-inhibitoren
|
MX2009008099A
(es)
|
2007-02-01 |
2009-12-14 |
Resverlogix Corp |
Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares.
|
GEP20125581B
(en)
|
2007-04-18 |
2012-07-25 |
Pfizer Prod Inc |
Sulfonyl amide derivatives for treatment of abnormal cell growth
|
US8530463B2
(en)
|
2007-05-07 |
2013-09-10 |
Hale Biopharma Ventures Llc |
Multimodal particulate formulations
|
CA2924418A1
(en)
|
2007-07-30 |
2009-02-05 |
Jean-Michel Vernier |
Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same
|
NZ586802A
(en)
|
2007-12-19 |
2012-03-30 |
Genentech Inc |
Imidazo[1,5-a]pyridine and imidazo[1,5-a]pyrazine derivatives for the treatment of inflammatory diseases
|
CA2708176A1
(en)
|
2007-12-21 |
2009-07-02 |
Genentech, Inc. |
Azaindolizines and methods of use
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
EP3613743B1
(de)
|
2008-01-04 |
2022-03-16 |
Intellikine, LLC |
Verfahren zur herstellung von 1h-pyrazolo[3,4-d]pyrimidin-4-amin-derivaten
|
WO2009114870A2
(en)
|
2008-03-14 |
2009-09-17 |
Intellikine, Inc. |
Kinase inhibitors and methods of use
|
JP5613657B2
(ja)
|
2008-03-28 |
2014-10-29 |
ヘイル バイオファーマ ベンチャーズ,エルエルシー |
ベンゾジアゼピン組成物の投与
|
SI2346837T1
(sl)
|
2008-06-26 |
2015-05-29 |
Resverlogix Corporation |
Postopki pripravljanja kinazolinonskih derivatov
|
CA2730106A1
(en)
|
2008-07-08 |
2010-01-14 |
Intellikine, Inc. |
Kinase inhibitors and methods of use
|
EP2147684A1
(de)
|
2008-07-22 |
2010-01-27 |
Bracco Imaging S.p.A |
Selektiv gegen Metallproteasen wirkende Diagnosemittel
|
EP2149568A1
(de)
|
2008-07-22 |
2010-02-03 |
Bracco Imaging S.p.A |
Aryl-sulphonamid-dimere als metallprotease-hemmer
|
EP2334701A4
(de)
|
2008-10-16 |
2014-01-08 |
Univ Pittsburgh |
Vollständig menschliche antikörper gegen mit melanomen von hohem molekulargewicht assoziierte antigene und verwendungen davon
|
US8476431B2
(en)
|
2008-11-03 |
2013-07-02 |
Itellikine LLC |
Benzoxazole kinase inhibitors and methods of use
|
US8952021B2
(en)
|
2009-01-08 |
2015-02-10 |
Resverlogix Corp. |
Compounds for the prevention and treatment of cardiovascular disease
|
AU2010210646B2
(en)
|
2009-02-05 |
2015-10-29 |
Immunogen, Inc. |
Novel benzodiazepine derivatives
|
CN102307875A
(zh)
|
2009-02-09 |
2012-01-04 |
苏伯俭股份有限公司 |
吡咯并嘧啶基axl激酶抑制剂
|
WO2010099139A2
(en)
|
2009-02-25 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Combination anti-cancer therapy
|
US20110171124A1
(en)
|
2009-02-26 |
2011-07-14 |
Osi Pharmaceuticals, Inc. |
In situ methods for monitoring the EMT status of tumor cells in vivo
|
EP2401613A2
(de)
|
2009-02-27 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Verfahren zur identifizierung von mesenchymähnlichen tumorzellen oder deren bildung hemmenden stoffen
|
US8642834B2
(en)
|
2009-02-27 |
2014-02-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
TW201035088A
(en)
|
2009-02-27 |
2010-10-01 |
Supergen Inc |
Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
CA3146333A1
(en)
|
2009-03-18 |
2010-09-23 |
Resverlogix Corp. |
Phenyl-quinazolin-4(3h)-one and phenyl-pyrido[2,3-d]pyrimidin-4(3h)-one derivatives and compositions thereof useful as anti-inflammatory agents
|
WO2010108652A1
(en)
|
2009-03-27 |
2010-09-30 |
Ardea Biosciences Inc. |
Dihydropyridin sulfonamides and dihydropyridin sulfamides as mek inhibitors
|
PL2421533T3
(pl)
|
2009-04-22 |
2019-05-31 |
Resverlogix Corp |
Nowe środki przeciwzapalne
|
CA2760791C
(en)
|
2009-05-07 |
2017-06-20 |
Intellikine, Inc. |
Heterocyclic compounds and uses thereof
|
EP2459191A1
(de)
|
2009-07-31 |
2012-06-06 |
OSI Pharmaceuticals, LLC |
Kombinationstherapie aus mtor-hemmer und angiogenese-hemmer
|
SI2467141T1
(sl)
|
2009-08-17 |
2019-03-29 |
Intellikine, Llc |
Heterociklične spojine in njihove uporabe
|
CA2772194A1
(en)
|
2009-09-01 |
2011-03-10 |
Pfizer Inc. |
Benzimidazole derivatives
|
JP5892612B2
(ja)
|
2009-10-13 |
2016-03-23 |
アロメック セラピューティクス エルエルシーAllomek Therapeutics Llc |
疾患の処置に有用な新規のmek阻害剤
|
WO2011049625A1
(en)
|
2009-10-20 |
2011-04-28 |
Mansour Samadpour |
Method for aflatoxin screening of products
|
KR101821768B1
(ko)
|
2009-11-05 |
2018-01-24 |
리젠 파마슈티컬스 소시에떼 아노님 |
신규한 벤조피란 키나제 조절제
|
CN105001334A
(zh)
|
2010-02-10 |
2015-10-28 |
伊缪诺金公司 |
Cd20抗体及其用途
|
PT2534153T
(pt)
|
2010-02-12 |
2016-12-27 |
Pfizer |
Sais e polimorfos de 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona
|
AU2011223643A1
(en)
|
2010-03-03 |
2012-06-28 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
WO2011109584A2
(en)
|
2010-03-03 |
2011-09-09 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
NZ703111A
(en)
|
2010-05-17 |
2016-07-29 |
Incozen Therapeutics Pvt Ltd |
Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
|
JP5951600B2
(ja)
|
2010-05-21 |
2016-07-13 |
インフィニティー ファーマシューティカルズ, インコーポレイテッド |
キナーゼ調節のための、化合物、組成物および方法
|
CN104689314B
(zh)
|
2010-06-16 |
2018-02-02 |
高等教育联邦系统-匹兹堡大学 |
内质蛋白的抗体及其用途
|
US9738604B2
(en)
|
2010-09-03 |
2017-08-22 |
Duke University |
Ethynylbenzene derivatives
|
EP2630134B9
(de)
|
2010-10-20 |
2018-04-18 |
Pfizer Inc |
Pyridine-2- derivate als modulatoren des smoothened rezeptors
|
US8901133B2
(en)
|
2010-11-10 |
2014-12-02 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
TWI659956B
(zh)
|
2011-01-10 |
2019-05-21 |
美商英菲尼提製藥股份有限公司 |
製備異喹啉酮之方法及異喹啉酮之固體形式
|
US20140037642A1
(en)
|
2011-02-02 |
2014-02-06 |
Amgen Inc. |
Methods and compositions relating to inhibition of igf-1r
|
KR20140010067A
(ko)
|
2011-02-15 |
2014-01-23 |
이뮤노젠 아이엔씨 |
컨쥬게이트의 제조방법
|
US20120214830A1
(en)
|
2011-02-22 |
2012-08-23 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
JP5808826B2
(ja)
|
2011-02-23 |
2015-11-10 |
インテリカイン, エルエルシー |
複素環化合物およびその使用
|
WO2012142164A1
(en)
|
2011-04-12 |
2012-10-18 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
|
ES2724801T3
(es)
|
2011-04-19 |
2019-09-16 |
Pfizer |
Combinaciones de anticuerpos anti-4-1BB y anticuerpos inductores de ADCC para el tratamiento del cáncer
|
WO2012149014A1
(en)
|
2011-04-25 |
2012-11-01 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
US9775841B2
(en)
|
2011-05-04 |
2017-10-03 |
Rhizen Pharmaceuticals Sa |
Compounds as modulators of protein kinases
|
EP4085899A1
(de)
|
2011-06-14 |
2022-11-09 |
Neurelis, Inc. |
Verabreichung von benzodiazepin
|
CN103930422A
(zh)
|
2011-07-19 |
2014-07-16 |
无限药品股份有限公司 |
杂环化合物及其用途
|
WO2013012918A1
(en)
|
2011-07-19 |
2013-01-24 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
PL3409278T3
(pl)
|
2011-07-21 |
2021-02-22 |
Sumitomo Pharma Oncology, Inc. |
Heterocykliczne inhibitory kinazy białkowej
|
CA2846431A1
(en)
|
2011-08-29 |
2013-03-07 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
RU2586330C2
(ru)
|
2011-09-16 |
2016-06-10 |
Пфайзер Инк. |
Твердые формы ингибитора диссоциации транстиретина
|
EA201490673A1
(ru)
|
2011-09-22 |
2014-06-30 |
Пфайзер Инк. |
Производные пирролопиримидина и пурина
|
US9630979B2
(en)
|
2011-09-29 |
2017-04-25 |
Infinity Pharmaceuticals, Inc. |
Inhibitors of monoacylglycerol lipase and methods of their use
|
EP3275902A1
(de)
|
2011-10-04 |
2018-01-31 |
IGEM Therapeutics Limited |
Ige anti-hmw-maa antikörper
|
JP5992049B2
(ja)
|
2011-11-01 |
2016-09-14 |
レスバーロジックス コーポレイション |
置換されたキナゾリノンのための経口速放性製剤
|
US20140286959A1
(en)
|
2011-11-08 |
2014-09-25 |
Pfizer Inc. |
Methods of Treating Inflammatory Disorders Using Anti-M-CSF Antibodies
|
EP2817004B1
(de)
|
2012-02-22 |
2018-04-11 |
The Regents of The University of Colorado, A Body Corporate |
Bouvardin-derivate und therapeutische verwendung davon
|
US9452215B2
(en)
|
2012-02-22 |
2016-09-27 |
The Regents Of The University Of Colorado |
Bourvadin derivatives and therapeutic uses thereof
|
NZ629499A
(en)
|
2012-03-30 |
2016-05-27 |
Rhizen Pharmaceuticals Sa |
Novel 3,5-disubstituted-3h-imidazo[4,5-b]pyridine and 3,5- disubstituted -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
EP2859017B1
(de)
|
2012-06-08 |
2019-02-20 |
Sutro Biopharma, Inc. |
Antikörper mit nichtnatürlichen stellenspezifischen aminosäureresten, verfahren zu deren herstellung und verfahren zu deren verwendung
|
ES2611788T3
(es)
|
2012-06-26 |
2017-05-10 |
Sutro Biopharma, Inc. |
Proteínas de Fc modificadas que comprenden residuos de aminoácidos no naturales específicos del sitio, conjugados de las mismas, métodos para su preparación y métodos para su uso
|
EP2887965A1
(de)
|
2012-08-22 |
2015-07-01 |
ImmunoGen, Inc. |
Zytotoxische benzodiazepin-derivate
|
SI2890402T1
(sl)
|
2012-08-31 |
2019-07-31 |
Sutro Biopharma, Inc. |
Modificirane aminokisline vsebujoče acido skupino
|
WO2014062838A2
(en)
|
2012-10-16 |
2014-04-24 |
Tolero Pharmaceuticals, Inc. |
Pkm2 modulators and methods for their use
|
IL291945A
(en)
|
2012-11-01 |
2022-06-01 |
Infinity Pharmaceuticals Inc |
Cancer treatment using pi3 kinase isoform modulators
|
WO2014080290A2
(en)
|
2012-11-21 |
2014-05-30 |
Rvx Therapeutics Inc. |
Cyclic amines as bromodomain inhibitors
|
US9765039B2
(en)
|
2012-11-21 |
2017-09-19 |
Zenith Epigenetics Ltd. |
Biaryl derivatives as bromodomain inhibitors
|
MX2015007921A
(es)
|
2012-12-21 |
2016-03-03 |
Zenith Epigenetics Corp |
Compuestos heterociclicos novedosos como inhibidores de bromodominio.
|
WO2014134486A2
(en)
|
2013-02-28 |
2014-09-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
EP2961434A2
(de)
|
2013-02-28 |
2016-01-06 |
ImmunoGen, Inc. |
Konjugate mit zellbindenden mitteln und zytostatika
|
PL2970205T3
(pl)
|
2013-03-14 |
2019-10-31 |
Tolero Pharmaceuticals Inc |
Inhibitory jak2 i alk2 oraz sposoby ich zastosowania
|
WO2014143659A1
(en)
|
2013-03-15 |
2014-09-18 |
Araxes Pharma Llc |
Irreversible covalent inhibitors of the gtpase k-ras g12c
|
NZ629037A
(en)
|
2013-03-15 |
2017-04-28 |
Infinity Pharmaceuticals Inc |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
AU2014239542A1
(en)
|
2013-03-15 |
2015-10-01 |
Araxes Pharma Llc |
Covalent inhibitors of KRas G12C
|
CA2906542A1
(en)
|
2013-03-15 |
2014-09-25 |
Intellikine, Llc |
Combination of kinase inhibitors and uses thereof
|
UY35464A
(es)
|
2013-03-15 |
2014-10-31 |
Araxes Pharma Llc |
Inhibidores covalentes de kras g12c.
|
KR20160013204A
(ko)
|
2013-05-30 |
2016-02-03 |
인피니티 파마슈티칼스, 인코포레이티드 |
Pi3 키나아제 동형단백질 조절제를 사용하는 암의 치료
|
WO2014194030A2
(en)
|
2013-05-31 |
2014-12-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
EP3019522B1
(de)
|
2013-07-10 |
2017-12-13 |
Sutro Biopharma, Inc. |
Antikörper mit mehreren ortsspezifischen nichtnatürlichen aminosäureresten, verfahren zu deren herstellung und verfahren zu deren verwendung
|
JP6458270B2
(ja)
|
2013-08-16 |
2019-01-30 |
デューク ユニバーシティ |
置換されたヒドロキサム酸化合物
|
WO2015024021A2
(en)
*
|
2013-08-16 |
2015-02-19 |
Duke University |
Antibacterial compounds
|
US9908851B2
(en)
|
2013-08-16 |
2018-03-06 |
Duke University |
2-piperidinyl substituted N,3-dihydroxybutanamides
|
CA2924584A1
(en)
|
2013-10-03 |
2015-04-09 |
Kura Oncology, Inc. |
Inhibitors of erk and methods of use
|
SG11201602445SA
(en)
|
2013-10-04 |
2016-04-28 |
Infinity Pharmaceuticals Inc |
Heterocyclic compounds and uses thereof
|
WO2015051241A1
(en)
|
2013-10-04 |
2015-04-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
TWI659021B
(zh)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Kras g12c之抑制劑
|
CN106488910B
(zh)
|
2013-10-10 |
2020-07-31 |
亚瑞克西斯制药公司 |
Kras g12c的抑制剂
|
WO2015054658A1
(en)
|
2013-10-11 |
2015-04-16 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
WO2015061204A1
(en)
|
2013-10-21 |
2015-04-30 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
UA115388C2
(uk)
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
|
WO2015155624A1
(en)
|
2014-04-10 |
2015-10-15 |
Pfizer Inc. |
Dihydropyrrolopyrimidine derivatives
|
WO2015168079A1
(en)
|
2014-04-29 |
2015-11-05 |
Infinity Pharmaceuticals, Inc. |
Pyrimidine or pyridine derivatives useful as pi3k inhibitors
|
BR112016024513A2
(pt)
|
2014-04-30 |
2017-08-15 |
Pfizer |
derivados de di-heterociclo ligados à cicloalquila
|
JP6230205B2
(ja)
|
2014-06-19 |
2017-11-15 |
アリアド ファーマシューティカルズ, インコーポレイテッド |
キナーゼ阻害のためのヘテロアリール化合物
|
WO2016001789A1
(en)
|
2014-06-30 |
2016-01-07 |
Pfizer Inc. |
Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
|
JP6811706B2
(ja)
|
2014-07-31 |
2021-01-13 |
ザ ホンコン ユニヴァーシティ オブ サイエンス アンド テクノロジー |
Epha4に対するヒトモノクローナル抗体及びそれらの使用
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
WO2016049524A1
(en)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
WO2016049568A1
(en)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Methods and compositions for inhibition of ras
|
ES2746839T3
(es)
|
2014-12-18 |
2020-03-09 |
Pfizer |
Derivados de pirimidina y triazina y su uso como inhibidores de AXL
|
EP3268007B1
(de)
|
2015-03-13 |
2022-11-09 |
Resverlogix Corp. |
Zusammensetzungen und therapeutische verfahren zur behandlung von komplementassoziierten erkrankungen
|
KR20180005178A
(ko)
|
2015-04-10 |
2018-01-15 |
아락세스 파마 엘엘씨 |
치환된 퀴나졸린 화합물 및 이의 사용방법
|
WO2016168540A1
(en)
|
2015-04-15 |
2016-10-20 |
Araxes Pharma Llc |
Fused-tricyclic inhibitors of kras and methods of use thereof
|
RU2717829C2
(ru)
|
2015-04-20 |
2020-03-26 |
Толеро Фармасьютикалз, Инк. |
Прогнозирование ответа на альвоцидиб с помощью анализа профиля митохондрий
|
WO2016178876A2
(en)
|
2015-05-01 |
2016-11-10 |
Cocrystal Pharma, Inc. |
Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
|
WO2016187316A1
(en)
|
2015-05-18 |
2016-11-24 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs having increased bioavailability
|
AR104020A1
(es)
|
2015-06-04 |
2017-06-21 |
Kura Oncology Inc |
Métodos y composiciones para inhibir la interacción de menina con proteínas mill
|
WO2017009751A1
(en)
|
2015-07-15 |
2017-01-19 |
Pfizer Inc. |
Pyrimidine derivatives
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
US10568887B2
(en)
|
2015-08-03 |
2020-02-25 |
Tolero Pharmaceuticals, Inc. |
Combination therapies for treatment of cancer
|
US10730867B2
(en)
|
2015-09-28 |
2020-08-04 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
EP3356353A1
(de)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitoren von kras-g12c-mutanten proteinen
|
EP3356359B1
(de)
|
2015-09-28 |
2021-10-20 |
Araxes Pharma LLC |
Inhibitoren von kras-g12c-mutanten proteinen
|
WO2017058915A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
WO2017058902A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
EP3356351A1
(de)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitoren von kras-g12c-mutanten proteinen
|
US10875842B2
(en)
|
2015-09-28 |
2020-12-29 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
WO2017070256A2
(en)
|
2015-10-19 |
2017-04-27 |
Araxes Pharma Llc |
Method for screening inhibitors of ras
|
CA3005089A1
(en)
|
2015-11-16 |
2017-05-26 |
Araxes Pharma Llc |
2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
|
SG11201804360XA
(en)
|
2015-12-03 |
2018-06-28 |
Agios Pharmaceuticals Inc |
Mat2a inhibitors for treating mtap null cancer
|
US9988357B2
(en)
|
2015-12-09 |
2018-06-05 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
CN109069664B
(zh)
|
2016-01-27 |
2022-05-13 |
苏特罗生物制药公司 |
抗cd74抗体偶联物,包含抗cd74抗体偶联物的组合物以及抗cd74抗体偶联物的使用方法
|
JP6919977B2
(ja)
|
2016-03-16 |
2021-08-18 |
クラ オンコロジー,インク. |
メニン−mllの置換された阻害剤及びその使用方法
|
JP7000333B2
(ja)
|
2016-03-16 |
2022-02-10 |
クラ オンコロジー,インク. |
メニン-mllの架橋された二環式阻害剤及びその使用方法
|
WO2017172979A1
(en)
|
2016-03-30 |
2017-10-05 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
ES2910787T3
(es)
|
2016-05-12 |
2022-05-13 |
Univ Michigan Regents |
Inhibidores de ASH1L y métodos de tratamiento con los mismos
|
WO2017201302A1
(en)
|
2016-05-18 |
2017-11-23 |
The University Of Chicago |
Btk mutation and ibrutinib resistance
|
US10919914B2
(en)
|
2016-06-08 |
2021-02-16 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
WO2018045379A1
(en)
|
2016-09-02 |
2018-03-08 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of treating b cell disorders
|
JP2019529484A
(ja)
|
2016-09-29 |
2019-10-17 |
アラクセス ファーマ エルエルシー |
Kras g12c変異体タンパク質の阻害剤
|
WO2018068017A1
(en)
|
2016-10-07 |
2018-04-12 |
Araxes Pharma Llc |
Heterocyclic compounds as inhibitors of ras and methods of use thereof
|
US11279694B2
(en)
|
2016-11-18 |
2022-03-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
WO2018098352A2
(en)
|
2016-11-22 |
2018-05-31 |
Jun Oishi |
Targeting kras induced immune checkpoint expression
|
RU2632703C1
(ru)
*
|
2016-12-12 |
2017-10-09 |
федеральное государственное автономное образовательное учреждение высшего образования "Южный федеральный университет" |
Средство для ингибирования метастазирования в легких
|
JP6619519B2
(ja)
|
2016-12-19 |
2019-12-11 |
トレロ ファーマシューティカルズ, インコーポレイテッド |
プロファイリングペプチドおよび感受性プロファイリングのための方法
|
AU2017379074C9
(en)
|
2016-12-22 |
2023-06-08 |
Amgen Inc. |
Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as KRAS G12C inhibitors for treating lung, pancreatic or colorectal cancer
|
CN110382482A
(zh)
|
2017-01-26 |
2019-10-25 |
亚瑞克西斯制药公司 |
稠合的杂-杂二环化合物及其使用方法
|
AU2018213718B2
(en)
|
2017-01-26 |
2022-08-25 |
Zlip Holding Limited |
CD47 antigen binding unit and uses thereof
|
US11274093B2
(en)
|
2017-01-26 |
2022-03-15 |
Araxes Pharma Llc |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
US11358959B2
(en)
|
2017-01-26 |
2022-06-14 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
EP3573970A1
(de)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
1-(6-(3-hydroxynaphthalin-1-yl)chinazolin-2-yl)azetidin-1-yl)prop-2-en-1-on-derivate und ähnliche verbindungen wie kras g12c-inhibitoren zur behandlung von krebs
|
US11279689B2
(en)
|
2017-01-26 |
2022-03-22 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
|
US20200385364A1
(en)
|
2017-01-26 |
2020-12-10 |
Araxes Pharma Llc |
Fused n-heterocyclic compounds and methods of use thereof
|
WO2018175746A1
(en)
|
2017-03-24 |
2018-09-27 |
Kura Oncology, Inc. |
Methods for treating hematological malignancies and ewing's sarcoma
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
CN110831933A
(zh)
|
2017-05-25 |
2020-02-21 |
亚瑞克西斯制药公司 |
喹唑啉衍生物作为突变kras、hras或nras的调节剂
|
TW201906832A
(zh)
|
2017-05-25 |
2019-02-16 |
美商亞瑞克西斯製藥公司 |
用於癌症治療之化合物及其使用方法
|
CA3063440A1
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Covalent inhibitors of kras
|
US11542248B2
(en)
|
2017-06-08 |
2023-01-03 |
Kura Oncology, Inc. |
Methods and compositions for inhibiting the interaction of menin with MLL proteins
|
US20200207859A1
(en)
|
2017-07-26 |
2020-07-02 |
Sutro Biopharma, Inc. |
Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
|
ES2928576T3
(es)
|
2017-09-08 |
2022-11-21 |
Amgen Inc |
Inhibidores de KRAS G12C y métodos de uso de los mismos
|
JP7196160B2
(ja)
|
2017-09-12 |
2022-12-26 |
スミトモ ファーマ オンコロジー, インコーポレイテッド |
Mcl-1阻害剤アルボシジブを用いた、bcl-2阻害剤に対して非感受性である癌の治療レジメン
|
US10596270B2
(en)
|
2017-09-18 |
2020-03-24 |
Sutro Biopharma, Inc. |
Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates
|
US11649251B2
(en)
|
2017-09-20 |
2023-05-16 |
Kura Oncology, Inc. |
Substituted inhibitors of menin-MLL and methods of use
|
US20200237766A1
(en)
|
2017-10-13 |
2020-07-30 |
Tolero Pharmaceuticals, Inc. |
Pkm2 activators in combination with reactive oxygen species for treatment of cancer
|
EP3706737A4
(de)
|
2017-11-10 |
2021-10-20 |
The Regents of the University of Michigan |
Ash11-inhibitoren und verfahren zur behandlung damit
|
CN112040947A
(zh)
|
2017-12-07 |
2020-12-04 |
密歇根大学董事会 |
Nsd家族抑制剂及用其进行治疗的方法
|
WO2019195753A1
(en)
|
2018-04-05 |
2019-10-10 |
Tolero Pharmaceuticals, Inc. |
Axl kinase inhibitors and use of the same
|
MA52501A
(fr)
|
2018-05-04 |
2021-03-10 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
MX2020011582A
(es)
|
2018-05-04 |
2020-11-24 |
Amgen Inc |
Inhibidores de kras g12c y metodos para su uso.
|
MX2020011907A
(es)
|
2018-05-10 |
2021-01-29 |
Amgen Inc |
Inhibidores de kras g12c para el tratamiento de cancer.
|
AU2019278998B2
(en)
|
2018-06-01 |
2023-11-09 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
EP4155293A1
(de)
|
2018-06-07 |
2023-03-29 |
The Regents of The University of Michigan |
Prc1-inhibitoren und verfahren zur behandlung damit
|
MX2020012204A
(es)
|
2018-06-11 |
2021-03-31 |
Amgen Inc |
Inhibidores de kras g12c para tratar el cáncer.
|
US11285156B2
(en)
|
2018-06-12 |
2022-03-29 |
Amgen Inc. |
Substituted piperazines as KRAS G12C inhibitors
|
EP3826684A4
(de)
|
2018-07-26 |
2022-04-06 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Verfahren zur behandlung von mit abnormaler acvr1 -expression verbundenen krankheiten und acvr1 -inhibitoren zur verwendung in demselben
|
BR112021001709A2
(pt)
|
2018-08-01 |
2021-05-04 |
Araxes Pharma Llc |
compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer
|
EP3852811A1
(de)
|
2018-09-17 |
2021-07-28 |
Sutro Biopharma, Inc. |
Kombinationstherapien mit anti-folat-rezeptor-antikörper-konjugaten
|
EP3870585A1
(de)
|
2018-10-24 |
2021-09-01 |
Araxes Pharma LLC |
2-(2-acryloyl-2,6-diazaspiro[3.4]octan-6-yl)-6-(1h-indazol-4-yl)-benzonitrilderivate und verwandte verbindungen als hemmer des g12c-mutierten kras-proteins zur hemmung der tumormetastasierung
|
JP7516029B2
(ja)
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
AU2019384118A1
(en)
|
2018-11-19 |
2021-05-27 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
EP3887373A1
(de)
|
2018-11-29 |
2021-10-06 |
Araxes Pharma LLC |
Verbindungen und verwendungsverfahren dafür zur behandlung von krebs
|
KR20210099066A
(ko)
|
2018-12-04 |
2021-08-11 |
스미토모 다이니폰 파마 온콜로지, 인크. |
암의 치료를 위한 작용제로서 사용하기 위한 cdk9 억제제 및 그의 다형체
|
MA54550A
(fr)
|
2018-12-20 |
2022-03-30 |
Amgen Inc |
Inhibiteurs de kif18a
|
MX2021007156A
(es)
|
2018-12-20 |
2021-08-16 |
Amgen Inc |
Inhibidores de kif18a.
|
WO2020132653A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
WO2020132649A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
CN113412262A
(zh)
|
2019-02-12 |
2021-09-17 |
大日本住友制药肿瘤公司 |
包含杂环蛋白激酶抑制剂的制剂
|
KR20210146288A
(ko)
|
2019-03-01 |
2021-12-03 |
레볼루션 메디슨즈, 인크. |
이환식 헤테로사이클릴 화합물 및 이의 용도
|
EP3931195A1
(de)
|
2019-03-01 |
2022-01-05 |
Revolution Medicines, Inc. |
Bicyclische heteroarylverbindungen und verwendungen davon
|
JP2022525149A
(ja)
|
2019-03-20 |
2022-05-11 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置
|
WO2020198077A1
(en)
|
2019-03-22 |
2020-10-01 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Compositions comprising pkm2 modulators and methods of treatment using the same
|
EP3962951A1
(de)
|
2019-05-03 |
2022-03-09 |
Sutro Biopharma, Inc. |
Anti-bcma-antikörper-konjugate
|
EP3738593A1
(de)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosierung von kras-inhibitor zur behandlung von krebserkrankungen
|
CN114144414A
(zh)
|
2019-05-21 |
2022-03-04 |
美国安进公司 |
固态形式
|
AU2020300619A1
(en)
|
2019-07-03 |
2022-01-27 |
Sumitomo Pharma Oncology, Inc. |
Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
|
EP4007756A1
(de)
|
2019-08-02 |
2022-06-08 |
Amgen Inc. |
Kif18a-inhibitoren
|
CA3146693A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
US20220372018A1
(en)
|
2019-08-02 |
2022-11-24 |
Amgen Inc. |
Kif18a inhibitors
|
CA3147272A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
WO2021055728A1
(en)
|
2019-09-18 |
2021-03-25 |
Merck Sharp & Dohme Corp. |
Small molecule inhibitors of kras g12c mutant
|
TW202126636A
(zh)
|
2019-09-30 |
2021-07-16 |
美商阿吉歐斯製藥公司 |
作為menin抑制劑之六氫吡啶化合物
|
MX2022004656A
(es)
|
2019-10-24 |
2022-05-25 |
Amgen Inc |
Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
|
AU2020372881A1
(en)
|
2019-10-28 |
2022-06-09 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of KRAS G12C mutant
|
CN115551500A
(zh)
|
2019-10-31 |
2022-12-30 |
大鹏药品工业株式会社 |
4-氨基丁-2-烯酰胺衍生物及其盐
|
US11739074B2
(en)
|
2019-11-04 |
2023-08-29 |
Revolution Medicines, Inc. |
Ras inhibitors
|
JP2022553858A
(ja)
|
2019-11-04 |
2022-12-26 |
レボリューション メディシンズ インコーポレイテッド |
Ras阻害剤
|
EP4055028A1
(de)
|
2019-11-04 |
2022-09-14 |
Revolution Medicines, Inc. |
Ras-inhibitoren
|
WO2021092115A1
(en)
|
2019-11-08 |
2021-05-14 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
CA3161156A1
(en)
|
2019-11-14 |
2021-05-20 |
Amgen Inc. |
Improved synthesis of kras g12c inhibitor compound
|
JP2023501528A
(ja)
|
2019-11-14 |
2023-01-18 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の改善された合成
|
JP2023505100A
(ja)
|
2019-11-27 |
2023-02-08 |
レボリューション メディシンズ インコーポレイテッド |
共有ras阻害剤及びその使用
|
WO2021106231A1
(en)
|
2019-11-29 |
2021-06-03 |
Taiho Pharmaceutical Co., Ltd. |
A compound having inhibitory activity against kras g12d mutation
|
AU2021206217A1
(en)
|
2020-01-07 |
2022-09-01 |
Revolution Medicines, Inc. |
SHP2 inhibitor dosing and methods of treating cancer
|
WO2021155006A1
(en)
|
2020-01-31 |
2021-08-05 |
Les Laboratoires Servier Sas |
Inhibitors of cyclin-dependent kinases and uses thereof
|
WO2021178597A1
(en)
|
2020-03-03 |
2021-09-10 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
TW202204334A
(zh)
|
2020-04-08 |
2022-02-01 |
美商阿吉歐斯製藥公司 |
Menin抑制劑及治療癌症之使用方法
|
WO2021204159A1
(en)
|
2020-04-08 |
2021-10-14 |
Agios Pharmaceuticals, Inc. |
Menin inhibitors and methods of use for treating cancer
|
US20230181536A1
(en)
|
2020-04-24 |
2023-06-15 |
Taiho Pharmaceutical Co., Ltd. |
Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
|
WO2021215544A1
(en)
|
2020-04-24 |
2021-10-28 |
Taiho Pharmaceutical Co., Ltd. |
Kras g12d protein inhibitors
|
IL299131A
(en)
|
2020-06-18 |
2023-02-01 |
Revolution Medicines Inc |
Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
|
JP2023533982A
(ja)
|
2020-07-10 |
2023-08-07 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
Gas41阻害剤及びその使用方法
|
AU2021308045B2
(en)
|
2020-07-15 |
2024-06-20 |
Taiho Pharmaceutical Co., Ltd. |
Pyrimidine compound-containing combination to be used in tumor treatment
|
CN116209438A
(zh)
|
2020-09-03 |
2023-06-02 |
锐新医药公司 |
使用sos1抑制剂治疗具有shp2突变的恶性疾病
|
CN117683049A
(zh)
|
2020-09-15 |
2024-03-12 |
锐新医药公司 |
作为ras抑制剂以治疗癌症的吲哚衍生物
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Alk﹘5抑制劑和彼之用途
|
JP2024501280A
(ja)
|
2020-12-22 |
2024-01-11 |
キル・レガー・セラピューティクス・インコーポレーテッド |
Sos1阻害剤およびその使用
|
MX2023012060A
(es)
|
2021-04-13 |
2024-01-22 |
Nuvalent Inc |
Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr.
|
KR20240004659A
(ko)
|
2021-04-30 |
2024-01-11 |
셀진 코포레이션 |
감마 세크레타제 억제제(gsi)와 병용하여 항-bcma 항체-약물 접합체(adc)를 사용하는 병용 요법
|
KR20240017811A
(ko)
|
2021-05-05 |
2024-02-08 |
레볼루션 메디슨즈, 인크. |
암의 치료를 위한 ras 억제제
|
CN117500811A
(zh)
|
2021-05-05 |
2024-02-02 |
锐新医药公司 |
共价ras抑制剂及其用途
|
AU2022270116A1
(en)
|
2021-05-05 |
2023-12-21 |
Revolution Medicines, Inc. |
Ras inhibitors
|
WO2022250170A1
(en)
|
2021-05-28 |
2022-12-01 |
Taiho Pharmaceutical Co., Ltd. |
Small molecule inhibitors of kras mutated proteins
|
WO2023056589A1
(en)
|
2021-10-08 |
2023-04-13 |
Servier Pharmaceuticals Llc |
Menin inhibitors and methods of use for treating cancer
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
WO2023114954A1
(en)
|
2021-12-17 |
2023-06-22 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
EP4227307A1
(de)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazinverbindungen als shp2-inhibitoren
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
TW202412755A
(zh)
|
2022-04-25 |
2024-04-01 |
美商耐斯泰德醫療公司 |
促分裂原活化蛋白激酶(mek)抑制劑
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
US20240058465A1
(en)
|
2022-06-30 |
2024-02-22 |
Sutro Biopharma, Inc. |
Anti-ror1 antibody conjugates, compositions comprising anti ror1 antibody conjugates, and methods of making and using anti-ror1 antibody conjugates
|
WO2024010925A2
(en)
|
2022-07-08 |
2024-01-11 |
Nested Therapeutics, Inc. |
Mitogen-activated protein kinase (mek) inhibitors
|
WO2024081916A1
(en)
|
2022-10-14 |
2024-04-18 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|